Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6, 2013

Auxilium Pharmaceuticals to Announce Third Quarter 2013 Results on November 6,
                                     2013

PR Newswire

CHESTERBROOK, Pa., Oct. 24, 2013

CHESTERBROOK, Pa., Oct. 24, 2013 /PRNewswire/ --Auxilium Pharmaceuticals,
Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company,
will release results for the third quarter 2013 on Wednesday, November 6,
2013. The Company will also conduct a conference call that day at 10:00 a.m.
ET to discuss results and highlights of the third quarter. The presentation
slides to be used during the call will be available on the "For Investors"
section of the Company's web site under the "Presentations" tab beginning at
7:00 a.m. ET on Wednesday, November 6, 2013. A web cast of the conference
call and the presentation slides will be available on the "For Investors"
section of the Company's web site under the "Events" tab beginning at 10:00
a.m. ET on Wednesday, November 6, 2013. A question and answer session will
follow the presentation.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Mr. Adrian Adams, Chief Executive Officer and President, will host the
conference call.

Conference call details:
Date:                                                     Wednesday, November 6,
                                                          2013
Time: 10:00 a.m. ET
Dial-in (U.S.):                                           800-510-0219
Dial-in (International):                                  617-614-3451
Web cast:                                                 http://www.auxilium.com
Passcode:                                                 AUXILIUM
To access an audio replay of the call:
Access number (U.S.):                                     888-286-8010
Access number (International):                            617-801-6888
Replay Passcode #:                                        90298181

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® (testosterone gel) for the topical
treatment of hypogonadism in the U.S. and XIAFLEX (collagenase clostridium
histolyticum or CCH) for the treatment of adult Dupuytren's contracture
patients with a palpable cord in the U.S. Ferring International Center S.A.
markets Testim in certain countries of the EU and Paladin Labs Inc. markets
Testim in Canada. Swedish Orphan Biovitrium AB has marketing rights for
XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71
Eurasian and African countries. Asahi Kasei Pharma Corporation has
development and commercial rights for XIAFLEX in Japan and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. Auxilium also markets TESTOPEL®, a
long-acting implantable testosterone replacement therapy, Edex®, the leading
branded non-oral drug for erectile dysfunction, Striant®, a buccal system for
testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile
dysfunction, and also has a non-promoted respiratory franchise, including
Theo-24® and Semprex®-D, along with three other non-promoted products, in the
U.S. Auxilium has exclusive marketing rights in the U.S. and Canada for
STENDRA^TM, an oral erectile dysfunction therapy. Auxilium has three projects
in clinical development. XIAFLEX is currently under regulatory review by the
U.S. FDA for the treatment of Peyronie's disease. CCH is in Phase 2 of
development for the treatment of Frozen Shoulder syndrome (adhesive
capsulitis) and Phase 2 of development for the treatment of cellulite
(edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue
additional indications for XIAFLEX. For additional information, visit
http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995

This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to Auxilium's strategy, progress and timing of development
programs and related trials, the efficacy of its product candidates, the
commercial benefits available to it as a result of its agreements with third
parties, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management and other statements
regarding matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or prospects
to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed in Auxilium's filings with the Securities and Exchange Commission
(the "SEC"). While Auxilium may elect to update the forward-looking statements
made in this news release in the future, Auxilium specifically disclaims any
obligation to do so. Auxilium's SEC filings may be accessed electronically by
means of the SEC's home page on the Internet at http://www.sec.gov. There may
be additional risks that Auxilium does not presently know or that Auxilium
currently believes are immaterial which could also cause actual results to
differ from those contained in the forward-looking statements.

AUXILIUM CONTACTS:

James E. Fickenscher / CFONichol Ochsner/ Senior
Director, IR
Auxilium Pharmaceuticals, Inc.Auxilium
Pharmaceuticals, Inc.
(484) 321-5900   (484) 321-5900
jfickenscher@auxilium.com nochsner@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com/